Year-end Sale % OFF 
Abstract
Small cell lung cancer (SCLC) is typified by early recurrence and metastasis associated with many genetic changes. The drug ROVA-T composed of the DLL3 antibody Rovalpituzumab and the cytoto-xic drug Tesirine achieves the tumor-killing effect by releasing the Tesirine when bound to DLL3. Nfib promotes the SCLC metastasis by altering the structure of the chromosome. The PRAP, EZH2 and Wee1 inhibitors inhibit the DNA damage repair to improve the antitumor activity of chemotherapeutic drugs. Combination of Ipilimumab and Nivolumab can activate the human immune system to exert antitumor effect. Key words: Carcinoma, small cell; Immunotherapy; Targeted therapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
